Top Tweets for #CheckMate67T
CheckMate 67T: Subcutaneous nivolumab non-inferior to intravenous in advanced #RCC. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter to discuss the results of #CheckMate67T which met its co-primary pharmacokinetic endpoints, demonstrating non-inferiority of subcutaneous administration, while showing similar PFS and response rates between the two delivery methods. #WatchNow > https://t.co/cWTH3IRwEa
CheckMate 67T: Subcutaneous nivolumab non-inferior to intravenous in advanced #RCC. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter to discuss the results of #CheckMate67T which met its co-primary pharmacokinetic endpoints, demonstrating non-inferiority of subcutaneous administration, while showing similar PFS and response rates between the two delivery methods. #WatchNow > https://t.co/cWTH3IRwEa
CheckMate 67T: Subcutaneous nivolumab non-inferior to intravenous in advanced #RCC. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter to discuss the results of #CheckMate67T which met its co-primary pharmacokinetic endpoints, demonstrating non-inferiority of subcutaneous administration, while showing similar PFS and response rates between the two delivery methods. #WatchNow > https://t.co/cWTH3IRwEa
FDA approves #Nivolumab + hyaluronidase for subcutaneous injection! ⏱ Cuts administration to 3–5 mins vs. 30 mins IV, with consistent efficacy & safety. Indications include: #RCC, #Melanoma, #NSCLC, gastric cancer, & more. https://t.co/sQurrKoA4U #CheckMate67T @RoswellPark
CheckMate 67T: Subcutaneous nivolumab non-inferior to intravenous in advanced #RCC. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter to discuss the results of #CheckMate67T which met its co-primary pharmacokinetic endpoints, demonstrating non-inferiority of subcutaneous administration, while showing similar PFS and response rates between the two delivery methods. #WatchNow > https://t.co/cWTH3IRwEa
The #FDA has granted approval to #nivolumab and #hyaluronidase-nvhy for #subcutaneous injection across approved adult indications.
Read more about the #CheckMate67T trial that led to the #approval here!
https://t.co/vibSbkageA
🔥🚨@OncoAlert Hot off the press.
@US_FDA approved #Subcutaneous #Nivolumab for:
✅All adult indications in #SolidTumors
❌EXCEPT for combination with #Ipilimumab
Approval based on #CHECKMATE67T which showed similar #Efficacy & #Safety of #SQ vs #IV
👇🏼
https://t.co/Sd22oTAJEi
CheckMate 67T: Subcutaneous nivolumab non-inferior to intravenous in advanced #RCC. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter to discuss the results of #CheckMate67T which met its co-primary pharmacokinetic endpoints, demonstrating non-inferiority of subcutaneous administration, while showing similar PFS and response rates between the two delivery methods. #WatchNow > https://t.co/cWTH3IRwEa
Subcutaneous nivolumab vs intravenous nivolumab in patients with previously treated advanced or metastatic clear cell #RenalCellCarcinoma: updated efficacy and safety results from #CheckMate67T. Presented by @AlbigesL @GustaveRoussy > https://t.co/vFMgr1TpNT @chavarriagaj #ESMO24
Read the most recent #MashupMD collection from @GUOncologyNow: @tompowles1 discusses pivotal clinical data from #GU24, Dr. Saby George navigates through the exciting terrain of #CheckMate67T research, and more:
--
https://t.co/oekXWkI8fW
🎙️ ICYMI: Catch our latest video with Dr. Saby George on his #CheckMate67T research into subcutaneous #nivolumab for advanced or metastatic #ccRCC.
🎥 Watch Now: https://t.co/osQtk2gYPw
#CheckMate67T demonstrated that nivolumab subcutaneous demonstrated non-inferior pharmacokinetics and objective response compared to intravenous nivolumab.
--
See more from @DrRanaMcKay on #MashupMD:
https://t.co/OonBdv57BR
🎙️ Don't miss our latest video with Dr. Saby George on his #CheckMate67T research into subcutaneous #nivolumab for advanced or metastatic #ccRCC.
🎥 Watch Now: https://t.co/osQtk2gYPw
Key Advances in Prostate, Kidney, and Bladder Cancers Unveiled at GU24 - @nataliagandur
#ASCO #Cancer #CheckMate67T #KEYNOTE564 #OncoDaily #Oncology #CancerCare
https://t.co/qAANR4lPJ1
Dr. Saby George presented results from the #CheckMate67T trial evaluating the difference between #subcutaneous versus #intravenous #nivolumab in #ccRCC at #GU24. Learn More: https://t.co/lN6s6nBD8U
My late husband was a fainter. He hated it when I said that! But it was a necessary warning everytime he needed an IV. Sincere gratitude to Saby George and @bmsnews for #checkmate67T. Trials aimed at reducing treatment burden can make a meaningful difference for #kidneycancer pts.
Last Seen Hashtags on Sotwe
vishnupriya
Seen from Netherlands
ipcam()+filter:native_video
Seen from United States
incest asian
Seen from France
FanTasTik
Seen from Turkey
omegle
Seen from Spain
omegle()(*)+filter:media since:2026-09-06
Seen from Denmark
nolimit ometv filter:videos
Seen from Malaysia
pussyBoy
taboo
Seen from India
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.1M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.8M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73.1M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.1M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
62.9M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers